 | Up a level |
Andrieux-Meyer, Isabelle and Tan, Soek-Siam and Thanprasertsuk, Sombat and Salvadori, Nicolas and Menetrey, Caroline and Simon, Francois and Cressey, Tim R. and Said, Hajjah Rosaida Hj Mohd and Abu Hassan, Muhammad Radzi and Omar, Haniza and Tee, Hoi-Poh and Chan, Wah Kheong and Kumar, Suresh and Thongsawat, Satawat and Thetket, Kanawee and Avihingsanon, Anchalee and Khemnark, Suparat and Yerly, Sabine and Ngo-Giang-Huong, Nicole and Siva, Sasikala and Swanson, Alistair and Goyal, Vishal and Bompart, Francois and Pecoul, Bernard and Murad, Shahnaz (2021) Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet Gastroenterology & Hepatology, 6 (6). pp. 448-458. ISSN 2468-1253, DOI https://doi.org/10.1016/S2468-1253(21)00031-5.
